For information on 30 April 2020, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending that a marketing authorisation extension is granted for caplacizumab for ‘adolescents of 12 years of age and older weighing at least 40 kg. NICE have updated the Final scope to reflect this licence extension.